#China #Shanghai #WuXi Biologics #Drug Manufacturing #GMP Production

WuXi Biologics Launches 25th Drug Substance Facility

WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has made a significant milestone in its production capabilities by successfully completing its first GMP (Good Manufacturing Practice) production at its 25th drug substance facility, known as MFG17, located in Shanghai’s Fengxian district. This landmark achievement occurred without any deviations, showcasing the company’s robust capabilities in executing manufacturing processes.

A Groundbreaking Facility

The MFG17 facility is constructed with a focus on scalability, catering to a wide array of biologics that are crucial throughout both clinical and commercial stages. With a manufacturing capacity of 9,000 liters, this state-of-the-art site has the potential to handle approximately 80 to 100 batches annually. The execution of the initial production run maintained critical process parameters with remarkable stability, yielding results that met expectations and underscored the operational efficiency of the facility.

Equipped with multiple single-use bioreactors (SUBs), MFG17 can operate under various process modes such as fed-batch, N-1 perfusion, and fully automated continuous manufacturing. This versatility not only enhances productivity but also allows the facility to adapt to the specific needs of different projects throughout their development lifecycle.

Digital Transformation and Efficiency

In a move to elevate its operational standards, WuXi Biologics is also advancing its digital strategy by implementing automation and digital technologies across the manufacturing value chain. This initiative aims to enhance the operational management of the facility and translate data analysis and predictive modeling into more efficient production processes. This digital transformation is designed to provide clients with cost-competitive manufacturing solutions, which are critical in today's fast-paced biopharmaceutical industry.

Dr. Chris Chen, CEO of WuXi Biologics, emphasized that the successful achievement of the first GMP production at MFG17 not only bolsters their manufacturing capabilities but also strengthens the company's role in supporting customers' needs. By leveraging flexible single-use technologies and focusing on continual digital innovation, WuXi empowers global partners to accelerate the delivery of innovative biologics to patients across the globe.

Collaboration and Global Reach

The MFG17 facility will synergize closely with other operations at the Fengxian site, facilitating a seamless transition from drug discovery to development, clinical trials, and commercial manufacturing. This comprehensive integration is aimed at speeding up project timelines while enhancing quality and reliability in drug production.

As part of its global network, WuXi Biologics continues to improve its dual-sourcing strategy, supporting technology transfers and registrations across multiple regions. This strategy ensures long-term commercial supply resilience, enabling the company to navigate potential market challenges effectively. Currently, WuXi Biologics operates in numerous regions, including China, the United States, Ireland, Germany, and Singapore, with a vast array of research and manufacturing facilities in play.

The commitment to quality is evident with WuXi Biologics passing 46 regulatory inspections globally, including stringent checks by the European Medicines Agency (EMA) and the FDA, maintaining a stellar record with 100% compliance and no critical findings.

Industry Recognition

WuXi Biologics is recognized as a leader in the industry, showcasing its prestige by winning the 2026 Biologics CDMO of the Year and the Best Contract Development Manufacturing Organization Award in 2026. By continually driving sustainable practices and innovative solutions, the company positions itself at the forefront of the biopharmaceutical landscape.

Overall, WuXi Biologics’ successful first GMP production at the MFG17 facility signifies not only a pivotal moment in the company’s mission to improve global health through advanced biologics but also sets a new standard for quality and efficiency in the biopharmaceutical manufacturing sector.